Applying the Center for Medical Technology Policy’s (CMTP) Chain of Evidence for Clinical Utility to Prolaris, a Prognostic Prostate Cancer Test Developed by Myriad Genetic Laboratories
The CMTP in 2013 established best practices for generating evidence of clinical utility. Through its “Chain-of-Evidence” guidance, CMTP integrates analytic and clinical validity with an expanded definition of clinical utility, demonstrating that a diagnostic test can improve patient health outcomes, as well as quality of life and cost effectiveness.
Using the Prolaris prostate cancer prognostic test, we employ the CMTP chain-of-evidence format to demonstrate how it can be used to broaden clinical utility discussions between payers and providers beyond the traditional framework, thus facilitating a more rapid adoption of new technologies that improve member health and save health care dollars.
Myriad needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time.